Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab in Moderate to Severe Hidradenitis Suppurativa
NCT05139602Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of lutikizumab in hidradenitis suppurativa (HS), sponsored by AbbVie Inc.. Started Dec 2021; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05139602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139602.